TD Cowen raised the firm’s price target on Ultragenyx to $111 from $110. The firm said their 4Q23 report delivered a top-line beat driven by Crysvita sales above consensus, impressive in general, and particularly in the context of the commercial handover, its clearly going well.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RARE:
- Ultragenyx price target raised to $48 from $47 at Wedbush
- Ultragenyx sees FY24 revenue $500M-$530M, consensus $504.31M
- Ultragenyx reports Q4 EPS ($1.52), consensus ($1.62)
- Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
- RARE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
